60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • Friday
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialGlobeNewsWire • 11/11/24
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in AustraliaGlobeNewsWire • 11/04/24
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with PiclidenosonGlobeNewsWire • 10/18/24
FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic CancerGlobeNewsWire • 10/09/24
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of HealthGlobeNewsWire • 09/16/24
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesGlobeNewsWire • 08/29/24
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 08/09/24
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross ProceedsGlobeNewsWire • 08/08/24
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic CancerGlobeNewsWire • 07/11/24
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner VetbiolixBusiness Wire • 06/28/24
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the LiverBusiness Wire • 06/24/24
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa StudyBusiness Wire • 06/10/24
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart DiseasesBusiness Wire • 05/29/24
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024Business Wire • 05/27/24
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer StudyBusiness Wire • 05/13/24
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 05/10/24
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb StudyBusiness Wire • 05/09/24
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602Business Wire • 05/06/24
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific JournalBusiness Wire • 04/25/24
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASHBusiness Wire • 04/15/24